



# SAFETY DATA SHEET

Revision date 16-Jun-2025

Version 4

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
**Product Code(s)** PZ03177  
**Trade Name:** HEXTEND  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: This substance is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**  
Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**  
Not applicable

### 2.2. Label elements

**Signal word** Not classified

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 2 / 13  
Version 4

**Hazard statements** Not classified in accordance with international standards for workplace safety.

## **2.3. Other hazards** **Other hazards**

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**PBT & vPvB** The product does not contain any substance(s) classified as PBT or vPvB.

**Endocrine Disruptor Information** This product does not contain any known or suspected endocrine disruptors.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## **Section 3: COMPOSITION/INFORMATION ON INGREDIENTS**

### **3.1 Substances** **Substances**

Not applicable

### **3.2 Mixtures**

#### **Hazardous**

| Chemical name                            | Weight-% | REACH registration number | EC No (EU Index No) | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor          | M-Factor (long-term) |
|--|----------|---------------------------|---------------------|---|------------------------------------|-------------------|----------------------|
| Calcium chloride USP (CAS #: 10035-04-8) | <0.1     |                           | Not Listed          | Eye Irrit. 2 (H319)   | Not classified                     | No data available | No data available    |
| POTASSIUM CHLORIDE (CAS #: 7447-40-7)    | *        |                           | 231-211-8           | Acute Tox 5 (H303)  | Not classified                     | No data available | No data available    |

#### **NonHazardous**

| Chemical name                          | Weight-% | REACH registration number | EC No (EU Index No) | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor          | M-Factor (long-term) |
|--|----------|---------------------------|---------------------|---|------------------------------------|-------------------|----------------------|
| Water (CAS #: 7732-18-5)               | *        | -                         | 231-791-2           | Not classified  | Not classified                     | No data available | No data available    |
| Hydroxyethyl starch (CAS #: 9005-27-0) | 6        |                           | Not Listed          | Not classified  | Not classified                     | No data available | No data available    |
| SODIUM CHLORIDE (CAS #: 7647-14-5)     | *        | -                         | 231-598-3           | Not classified  | Not classified                     | No data available | No data available    |
| Sodium lactate (CAS #: 72-17-3)        | *        |                           | 200-772-0           | Not classified  | Not classified                     | No data available | No data available    |
| Dextrose                               | *        |                           | Not Listed          | Not classified  | Not classified                     | No data           | No data              |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 3 / 13  
Version 4

|   |   |  |            |                |                |                   |                   |
|---|---|--|------------|----------------|----------------|-------------------|-------------------|
| (CAS #: 14431-43-7)                               |   |  |            |                |                | available         | available         |
| Magnesium chloride hexahydrate (CAS #: 7791-18-6) | * |  | Not Listed | Not classified | Not classified | No data available | No data available |

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate

| Chemical name                            | Oral LD50 mg/kg   | Dermal LD50 mg/kg | Inhalation LC50 - 4 hour - dust/mist - mg/L | Inhalation LC50 - 4 hour - vapor - mg/L | Inhalation LC50 - 4 hour - gas - ppm |
|--|-------------------|-------------------|---|---|--------------------------------------|
| Water 7732-18-5                          | 89838.9           | No data available | No data available                           | No data available                       | No data available                    |
| Hydroxyethyl starch 9005-27-0            | 50000             | No data available | No data available                           | No data available                       | No data available                    |
| SODIUM CHLORIDE 7647-14-5                | 3550              | 10000             | No data available                           | No data available                       | No data available                    |
| Sodium lactate 72-17-3                   | No data available | 2000              | 7.94  | No data available                       | No data available                    |
| Calcium chloride USP 10035-04-8          | 1000              | No data available | No data available                           | No data available                       | No data available                    |
| POTASSIUM CHLORIDE 7447-40-7             | 3020              | No data available | No data available                           | No data available                       | No data available                    |
| Magnesium chloride hexahydrate 7791-18-6 | 8100              | No data available | No data available                           | No data available                       | No data available                    |

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

|                     |  |
|---------------------|--|
| <b>Inhalation</b>   | Remove to fresh air. Seek immediate medical attention/advice.  |
| <b>Eye contact</b>  | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.   |
| <b>Skin contact</b> | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.  |
| <b>Ingestion</b>    | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 4 / 13  
Version 4

## 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

## 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians** None.

## **Section 5: FIRE-FIGHTING MEASURES**

### 5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Fine particles (such as dust and mists) may fuel fires/explosions.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

#### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### 5.3. Advice for firefighters

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## **Section 6: ACCIDENTAL RELEASE MEASURES**

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 5 / 13  
Version 4

## 7.1. Precautions for safe handling

### Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

### Storage Conditions

Store as directed by product packaging.

## 7.3. Specific end use(s)

### Specific use(s)

Pharmaceutical product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Hydroxyethyl starch

Russia

MAC: 10 mg/m<sup>3</sup>

#### SODIUM CHLORIDE

Latvia

TWA: 5 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

#### POTASSIUM CHLORIDE

Bulgaria

TWA: 5.0 mg/m<sup>3</sup>;

Latvia

TWA: 5 mg/m<sup>3</sup>;

Russia

MAC: 5 mg/m<sup>3</sup>

#### Magnesium chloride hexahydrate

Russia

MAC: 2 mg/m<sup>3</sup>

#### Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

#### SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

#### POTASSIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

### 8.2. Exposure controls

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 6 / 13  
Version 4

|  |   |
|--|---|
| <b>Engineering controls</b>            | Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.  |
| <b>Personal protective equipment</b>   | Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes. |
| <b>Eye/face protection</b>             | Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).  |
| <b>Hand protection</b>                 | Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).   |
| <b>Skin and body protection</b>        | Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).  |
| <b>Respiratory protection</b>          | Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).                         |
| <b>Thermal hazards</b>                 | No information available.   |
| <b>Environmental exposure controls</b> | No information available.   |

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

|                       |                           |
|-----------------------|---------------------------|
| <b>Appearance</b>     | Liquid solution           |
| <b>Physical state</b> | Liquid                    |
| <b>Color</b>          | No information available  |
| <b>Odor</b>           | No information available. |
| <b>Odor threshold</b> | No information available  |

| <u>Property</u>   | <u>Values</u>     |
|---|-------------------|
| <b>Melting point / freezing point</b>                           | No data available |
| <b>Boiling point or initial boiling point and boiling range</b> | No data available |
| <b>Flammability (solid, gas)</b>                                | No data available |
| <b>Lower and upper explosion limit/flammability limit</b>       |                   |
| Lower explosion limit   | No data available |
| Upper explosion limit   | No data available |
| <b>Flash point</b>  | No data available |
| <b>Autoignition temperature</b>                                 | No data available |
| <b>Decomposition temperature</b>                                |                   |
| SADT (°C)   | No data available |
| <b>pH</b>   | No data available |
| pH (as aqueous solution)  | No data available |
| <b>Kinematic viscosity</b>                                      | No data available |
| Dynamic viscosity   | No data available |
| <b>Solubility</b>   | No data available |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 7 / 13  
Version 4

|                                 |                          |
|---------------------------------|--------------------------|
| Vapor pressure                  | No data available        |
| Density and/or relative density | No data available        |
| Bulk density                    | No data available        |
| Liquid Density                  | No data available        |
| Vapor density                   | No data available        |
| Particle characteristics        |                          |
| Particle Size                   | No information available |
| Particle Size Distribution      | No information available |

## 9.2. Other information

|                   |         |
|-------------------|---------|
| Molecular formula | Mixture |
| Molecular weight  | Mixture |

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## **Section 10: STABILITY AND REACTIVITY**

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under normal conditions.

### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

### 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

### 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## **Section 11: TOXICOLOGICAL INFORMATION**

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the individual ingredients

**Known Clinical Effects:** Serious allergic reactions, including anaphylaxis, have been reported. Adverse effects associated with therapeutic use include effects on cardiovascular system, blood clotting irregularities, bleeding, decreased red blood cell count (anemia), vomiting, headache, flu-like syndrome, swelling, muscle pain.

|                                   |   |
|-----------------------------------|---|
| Acute toxicity                    | Based on available data, the classification criteria are not met. |
| Serious eye damage/eye irritation | Based on available data, the classification criteria are not met. |
| Skin corrosion/irritation         | Based on available data, the classification criteria are not met. |
| Respiratory or skin sensitization | Based on available data, the classification criteria are not met. |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 8 / 13  
Version 4

**STOT - single exposure** Based on available data, the classification criteria are not met.  
**STOT - repeated exposure** Based on available data, the classification criteria are not met.  
**Reproductive toxicity** Based on available data, the classification criteria are not met.  
**Germ cell mutagenicity** Based on available data, the classification criteria are not met.  
**Carcinogenicity** Based on available data, the classification criteria are not met.  
**Aspiration hazard** Based on available data, the classification criteria are not met.

## **Acute Toxicity: (Species, Route, End Point, Dose)**

### **Hydroxyethyl starch**

Rat Oral LD50 > 50 g/kg

### **SODIUM CHLORIDE**

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

### **Sodium lactate**

Rat Oral LD50 > 90 mL/kg

### **Calcium chloride USP**

Rat Oral LD50 2301 mg/kg

Mouse Oral LD50 1940 mg/kg

Rabbit Dermal LD50 > 5000 mg/kg

### **POTASSIUM CHLORIDE**

Rat Oral LD50 3020 mg/kg

| Chemical name                  | Oral LD50            | Dermal LD50              | Inhalation LC50         |
|--------------------------------|----------------------|--------------------------|-------------------------|
| Water                          | > 90 mL/kg ( Rat )   | -                        | -                       |
| Hydroxyethyl starch            | > 50 g/kg ( Rat )    | -                        | -                       |
| SODIUM CHLORIDE                | = 3550 mg/kg ( Rat ) | > 10000 mg/kg ( Rabbit ) | > 42 mg/L ( Rat ) 1 h   |
| Sodium lactate                 |                      | > 2000 mg/kg ( Rabbit )  | > 7.94 mg/L ( Rat ) 4 h |
| POTASSIUM CHLORIDE             | = 2600 mg/kg ( Rat ) | -                        | -                       |
| Magnesium chloride hexahydrate | = 8100 mg/kg ( Rat ) | -                        | -                       |

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

## **Irritation / Sensitization: (Study Type, Species, Severity)**

### **SODIUM CHLORIDE**

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

### **Sodium lactate**

Eye Irritation Rabbit Mild

### **Calcium chloride USP**

Eye Irritation Rabbit Moderate

### **POTASSIUM CHLORIDE**

Eye Irritation Rabbit Mild

## **Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

### **Magnesium chloride hexahydrate**

13 Week(s) Mouse Oral 273 g/kg LOEL Kidney, Ureter, Bladder

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**



# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 9 / 13  
Version 4

## Hydroxyethyl starch

Embryo / Fetal Development Mouse Intravenous 60 mL/kg NOAEL Not teratogenic  
Embryo / Fetal Development Rabbit Intravenous 75 mL/kg NOAEL Not Teratogenic  
Embryo / Fetal Development Mouse Rat Intraperitoneal 50 g/kg NOAEL Not Teratogenic

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

### 12.1. Toxicity

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### POTASSIUM CHLORIDE

*Gambusia affinis* (Mosquitofish) LC50 96 hours 920 mg/L  
*Lepomis macrochirus* (Bluegill Sunfish) LC50 96 hours 2010 mg/L  
*Daphnia Magna* (Water Flea) EC50 48 hours 825 mg/L  
*Scenedesmus subspicatus* (Green Alga) EC50 72 hours 2500 mg/L

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

#### **PBT and vPvB assessment**

| Chemical name      | PBT and vPvB assessment                    |
|--------------------|--|
| SODIUM CHLORIDE    | Not PBT/vPvB PBT assessment does not apply |
| Sodium lactate     | Not PBT/vPvB                               |
| POTASSIUM CHLORIDE | Not PBT/vPvB PBT assessment does not apply |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 10 / 13  
Version 4

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

## 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

|                                    |                |
|------------------------------------|----------------|
| <b>UN number:</b>                  | Not applicable |
| <b>UN proper shipping name:</b>    | Not applicable |
| <b>Transport hazard class(es):</b> | Not applicable |
| <b>Packing group:</b>              | Not applicable |
| <b>Environmental Hazard(s):</b>    | Not applicable |

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

|   |            |
|---|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | 231-791-2  |
| <b>AICS</b>                                 | Present    |

Hydroxyethyl starch

|   |            |
|---|------------|
| <b>CERCLA/SARA Section 313 de minimus %</b> | Not Listed |
| <b>California Proposition 65</b>            | Not Listed |
| <b>TSCA</b>                                 | Present    |
| <b>EINECS</b>                               | Not Listed |

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 11 / 13  
Version 4

|   |            |
|---|------------|
| <b>AICS</b>   | Present    |
| <b>SODIUM CHLORIDE</b>  |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>TSCA</b>   | Present    |
| <b>EINECS</b>   | 231-598-3  |
| <b>AICS</b>   | Present    |
| <b>Sodium lactate</b>   |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>TSCA</b>   | Present    |
| <b>EINECS</b>   | 200-772-0  |
| <b>AICS</b>   | Present    |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 5 |
| <b>Dextrose</b>   |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>EINECS</b>   | Not Listed |
| <b>AICS</b>   | Present    |
| <b>Calcium chloride USP</b>   |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>EINECS</b>   | Not Listed |
| <b>AICS</b>   | Present    |
| <b>POTASSIUM CHLORIDE</b>   |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>TSCA</b>   | Present    |
| <b>EINECS</b>   | 231-211-8  |
| <b>AICS</b>   | Present    |
| <b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b> | Schedule 4 |
| <b>Magnesium chloride hexahydrate</b>                                   |            |
| <b>CERCLA/SARA Section 313 de minimus %</b>                             | Not Listed |
| <b>California Proposition 65</b>  | Not Listed |
| <b>EINECS</b>   | Not Listed |
| <b>AICS</b>   | Present    |

## National regulations

### France

#### Occupational Illnesses (R-463-3, France)

| Chemical name                   | French RG number |
|---------------------------------|------------------|
| SODIUM CHLORIDE<br>7647-14-5    | RG 78            |
| POTASSIUM CHLORIDE<br>7447-40-7 | RG 67            |

### Germany

#### Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

### **TRGS 905**

Not applicable

### Switzerland

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 12 / 13  
Version 4

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable  
**Storage of Hazardous Material** Not applicable  
**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable  
**Major Accidents Ordinance SR 814.012** Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

## Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## EU - Plant Protection Products (1107/2009/EC)

| Chemical name                | EU - Plant Protection Products (1107/2009/EC) |
|------------------------------|---|
| SODIUM CHLORIDE<br>7647-14-5 | Plant protection agent                        |

| Chemical name                | Biocidal Products Regulation (EU) No 528/2012 (BPR) |
|------------------------------|---|
| SODIUM CHLORIDE<br>7647-14-5 | Product-type 1: Human hygiene                       |

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory  
**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List  
**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances  
**ENCS** - Japan Existing and New Chemical Substances  
**IECSC** - China Inventory of Existing Chemical Substances  
**KECL** - Korean Existing Chemicals Inventory  
**PICCS** - Philippines Inventory of Chemicals and Chemical Substances  
**AICS** - Australian Inventory of Chemical Substances  
**NZIoC** - New Zealand Inventory of Chemicals  
**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H319 - Causes serious eye irritation H303 - May be harmful if swallowed.

# SAFETY DATA SHEET

Product Name Hetastarch in Lactated Electrolyte Injection (Hospira, Inc.)  
Revision date 16-Jun-2025

Page 13 / 13  
Version 4

---

**Data Sources:** Safety data sheets for individual ingredients. Publicly available toxicity information.

**Reason for revision** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

**Revision date** 16-Jun-2025

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**